FDA Grants Early Access to Breakthrough Pancreatic Cancer Drug
According to The New York Times and Reuters, the US Food and Drug Administration (FDA) has approved expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.
Pancreatic cancer is one of the most aggressive and lethal cancers, with a five-year survival rate of approximately 12%. Because early symptoms are often unnoticeable, most patients are diagnosed at advanced stages when treatment options are extremely limited. Daraxonrasib, developed by Revolution Medicines, is a targeted drug aimed at KRAS gene mutations—one of the most common oncogenic mutations in pancreatic cancer.
Under the FDA’s expanded access program (also known as “compassionate use”), eligible pancreatic cancer patients can receive the treatment before the drug is formally approved for market. This policy applies to patients who have no other available treatment options and are not eligible for clinical trials.
Reuters reported that the drug has shown encouraging efficacy data in early clinical trials. Among treated patients, some demonstrated significant tumor shrinkage, and the drug was well-tolerated. Revolution Medicines plans to submit a New Drug Application (NDA) to the FDA later this year, seeking formal approval.
The New York Times analysis noted that the field of pancreatic cancer treatment has long lacked major breakthroughs, and daraxonrasib represents a significant advance. KRAS mutations were once considered “undruggable,” but in recent years, advances in drug development technology have led to remarkable progress in KRAS-targeted therapeutic strategies.
According to American Cancer Society data, pancreatic cancer causes approximately 50,000 deaths annually in the United States, making it one of the deadliest cancers globally. The expanded access approval means some patients can obtain this potentially life-extending treatment sooner.
An oncologist at UW Health described the development as “exciting” but also cautioned patients and doctors to maintain realistic expectations, as long-term efficacy and safety data still require further validation.
Sources: The New York Times, Reuters, USA Today